{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:25:13Z","timestamp":1788305113822,"version":"build-2803163510"},"reference-count":154,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:00:00Z","timestamp":1689811200000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100009655","name":"Sunovion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015303","name":"Otsuka Pharmaceutical Development and Commercialization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015303","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s40263-023-01022-7","type":"journal-article","created":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T12:01:55Z","timestamp":1689854515000},"page":"545-570","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Increased Metabolic Potential, Efficacy, and Safety of Emerging Treatments in Schizophrenia"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7294-4834","authenticated-orcid":false,"given":"Jonathan M.","family":"Meyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7254-5646","authenticated-orcid":false,"given":"Christoph U.","family":"Correll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,20]]},"reference":[{"issue":"2","key":"1022_CR1","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/nrendo.2011.156","volume":"8","author":"M De Hert","year":"2011","unstructured":"De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011;8(2):114\u201326. https:\/\/doi.org\/10.1038\/nrendo.2011.156.","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"1022_CR2","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/wps.20204","volume":"14","author":"CU Correll","year":"2015","unstructured":"Correll CU, Detraux J, De Lepeleire J, De Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry. 2015;14(2):119\u201336. https:\/\/doi.org\/10.1002\/wps.20204.","journal-title":"World Psychiatry"},{"issue":"1","key":"1022_CR3","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/j.2051-5545.2011.tb00014.x","volume":"10","author":"M De Hert","year":"2011","unstructured":"De Hert M, Correll CU, Bobes J, Cetkovich-Bakmas M, Cohen D, Asai I, et al. Physical illness in patients with severe mental disorders. I. prevalence, impact of medications and disparities in health care. World Psychiatry. 2011;10(1):52\u201377. https:\/\/doi.org\/10.1002\/j.2051-5545.2011.tb00014.x.","journal-title":"World Psychiatry"},{"issue":"3","key":"1022_CR4","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1001\/jamapsychiatry.2016.3803","volume":"74","author":"T Pillinger","year":"2017","unstructured":"Pillinger T, Beck K, Gobjila C, Donocik JG, Jauhar S, Howes OD. Impaired glucose homeostasis in first-episode schizophrenia: a systematic review and meta-analysis. JAMA Psychiat. 2017;74(3):261\u20139. https:\/\/doi.org\/10.1001\/jamapsychiatry.2016.3803.","journal-title":"JAMA Psychiat"},{"issue":"1","key":"1022_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.31887\/DCNS.2018.20.1\/mdehert","volume":"20","author":"M De Hert","year":"2018","unstructured":"De Hert M, Detraux J, Vancampfort D. The intriguing relationship between coronary heart disease and mental disorders. Dialog Clin Neurosci. 2018;20(1):31\u201340. https:\/\/doi.org\/10.31887\/DCNS.2018.20.1\/mdehert.","journal-title":"Dialog Clin Neurosci."},{"key":"1022_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.564240","volume":"11","author":"J Smith","year":"2020","unstructured":"Smith J, Griffiths LA, Band M, Horne D. Cardiometabolic risk in first episode psychosis patients. Front Endocrinol (Lausanne). 2020;11: 564240. https:\/\/doi.org\/10.3389\/fendo.2020.564240.","journal-title":"Front Endocrinol (Lausanne)."},{"key":"1022_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12991-017-0133-7","volume":"16","author":"CU Correll","year":"2017","unstructured":"Correll CU, Ng-Mak DS, Stafkey-Mailey D, Farrelly E, Rajagopalan K, Loebel A. Cardiometabolic comorbidities, readmission, and costs in schizophrenia and bipolar disorder: a real-world analysis. Ann Gen Psychiatry. 2017;16:9. https:\/\/doi.org\/10.1186\/s12991-017-0133-7.","journal-title":"Ann Gen Psychiatry"},{"issue":"1","key":"1022_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055176","volume":"8","author":"M Nordentoft","year":"2013","unstructured":"Nordentoft M, Wahlbeck K, H\u00e4llgren J, Westman J, Osby U, Alinaghizadeh H, et al. Excess mortality, causes of death and life expectancy in 270,770 patients with recent onset of mental disorders in Denmark, Finland and Sweden. PLoS ONE. 2013;8(1): e55176. https:\/\/doi.org\/10.1371\/journal.pone.0055176.","journal-title":"PLoS ONE"},{"issue":"6","key":"1022_CR9","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.ahj.2005.02.007","volume":"150","author":"CH Hennekens","year":"2005","unstructured":"Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J. 2005;150(6):1115\u201321. https:\/\/doi.org\/10.1016\/j.ahj.2005.02.007.","journal-title":"Am Heart J"},{"issue":"2","key":"1022_CR10","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/wps.20994","volume":"21","author":"CU Correll","year":"2022","unstructured":"Correll CU, Solmi M, Croatto G, Schneider LK, Rohani-Montez SC, Fairley L, et al. Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors. World Psychiatry. 2022;21(2):248\u201371. https:\/\/doi.org\/10.1002\/wps.20994.","journal-title":"World Psychiatry"},{"issue":"10202","key":"1022_CR11","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/s0140-6736(19)31135-3","volume":"394","author":"M Huhn","year":"2019","unstructured":"Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939\u201351. https:\/\/doi.org\/10.1016\/s0140-6736(19)31135-3.","journal-title":"Lancet"},{"issue":"1","key":"1022_CR12","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/s2215-0366(19)30416-x","volume":"7","author":"T Pillinger","year":"2020","unstructured":"Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7(1):64\u201377. https:\/\/doi.org\/10.1016\/s2215-0366(19)30416-x.","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"1022_CR13","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/wps.21036","volume":"22","author":"A Burschinski","year":"2023","unstructured":"Burschinski A, Schneider-Thoma J, Chiocchia V, Schestag K, Wang D, Siafis S, et al. Metabolic side effects in persons with schizophrenia during mid- to long-term treatment with antipsychotics: a network meta-analysis of randomized controlled trials. World Psychiatry. 2023;22(1):116\u201328. https:\/\/doi.org\/10.1002\/wps.21036.","journal-title":"World Psychiatry"},{"issue":"9","key":"1022_CR14","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1176\/appi.ajp.2021.21010031","volume":"178","author":"M Solmi","year":"2021","unstructured":"Solmi M, Fiedorowicz J, Poddighe L, Delogu M, Miola A, H\u00f8ye A, et al. Disparities in screening and treatment of cardiovascular diseases in patients with mental disorders across the world: systematic review and meta-analysis of 47 observational studies. Am J Psychiatry. 2021;178(9):793\u2013803. https:\/\/doi.org\/10.1176\/appi.ajp.2021.21010031.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"1022_CR15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/(SICI)1096-8628(200021)97:1<12::AID-AJMG3>3.0.CO;2-U","volume":"97","author":"AG Cardno","year":"2000","unstructured":"Cardno AG, Gottesman II. Twin studies of schizophrenia: from bow-and-arrow concordances to star wars mx and functional genomics. Am J Med Genet. 2000;97(1):12\u20137.","journal-title":"Am J Med Genet"},{"issue":"6","key":"1022_CR16","doi-asserted-by":"publisher","first-page":"5075","DOI":"10.1007\/s12035-017-0708-y","volume":"55","author":"B Misiak","year":"2018","unstructured":"Misiak B, Stramecki F, Gaw\u0119da \u0141, Prochwicz K, S\u0105siadek MM, Moustafa AA, et al. Interactions between variation in candidate genes and environmental factors in the etiology of schizophrenia and bipolar disorder: a systematic review. Mol Neurobiol. 2018;55(6):5075\u2013100. https:\/\/doi.org\/10.1007\/s12035-017-0708-y.","journal-title":"Mol Neurobiol"},{"issue":"2\u20133","key":"1022_CR17","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.schres.2010.08.022","volume":"123","author":"PI Lin","year":"2010","unstructured":"Lin PI, Shuldiner AR. Rethinking the genetic basis for comorbidity of schizophrenia and type 2 diabetes. Schizophr Res. 2010;123(2\u20133):234\u201343. https:\/\/doi.org\/10.1016\/j.schres.2010.08.022.","journal-title":"Schizophr Res"},{"issue":"8","key":"1022_CR18","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1017\/s0033291718001812","volume":"49","author":"HC So","year":"2019","unstructured":"So HC, Chau KL, Ao FK, Mo CH, Sham PC. Exploring shared genetic bases and causal relationships of schizophrenia and bipolar disorder with 28 cardiovascular and metabolic traits. Psychol Med. 2019;49(8):1286\u201398. https:\/\/doi.org\/10.1017\/s0033291718001812.","journal-title":"Psychol Med"},{"issue":"6","key":"1022_CR19","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1093\/schbul\/sbw058","volume":"42","author":"JP Zhang","year":"2016","unstructured":"Zhang JP, Lencz T, Zhang RX, Nitta M, Maayan L, John M, et al. Pharmacogenetic associations of antipsychotic drug-related weight gain: a systematic review and meta-analysis. Schizophr Bull. 2016;42(6):1418\u201337. https:\/\/doi.org\/10.1093\/schbul\/sbw058.","journal-title":"Schizophr Bull"},{"issue":"2","key":"1022_CR20","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.molmed.2010.10.010","volume":"17","author":"CU Correll","year":"2011","unstructured":"Correll CU, Lencz T, Malhotra AK. Antipsychotic drugs and obesity. Trends Mol Med. 2011;17(2):97\u2013107. https:\/\/doi.org\/10.1016\/j.molmed.2010.10.010.","journal-title":"Trends Mol Med"},{"issue":"6","key":"1022_CR21","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1192\/bjp.bp.117.200907","volume":"211","author":"T Pillinger","year":"2017","unstructured":"Pillinger T, Beck K, Stubbs B, Howes OD. Cholesterol and triglyceride levels in first-episode psychosis: systematic review and meta-analysis. Br J Psychiatry. 2017;211(6):339\u201349. https:\/\/doi.org\/10.1192\/bjp.bp.117.200907.","journal-title":"Br J Psychiatry"},{"issue":"3","key":"1022_CR22","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1093\/schbul\/sbac001","volume":"48","author":"H Wu","year":"2022","unstructured":"Wu H, Siafis S, Hamza T, Schneider-Thoma J, Davis JM, Salanti G, et al. Antipsychotic-induced weight gain: dose\u2013response meta-analysis of randomized controlled trials. Schizophr Bull. 2022;48(3):643\u201354. https:\/\/doi.org\/10.1093\/schbul\/sbac001.","journal-title":"Schizophr Bull"},{"issue":"10","key":"1022_CR23","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1001\/jamapsychiatry.2019.1702","volume":"76","author":"T Masuda","year":"2019","unstructured":"Masuda T, Misawa F, Takase M, Kane JM, Correll CU. Association with hospitalization and all-cause discontinuation among patients with schizophrenia on clozapine vs other oral second-generation antipsychotics: a systematic review and meta-analysis of cohort studies. JAMA Psychiat. 2019;76(10):1052\u201362. https:\/\/doi.org\/10.1001\/jamapsychiatry.2019.1702.","journal-title":"JAMA Psychiat"},{"issue":"2","key":"1022_CR24","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/wps.20972","volume":"21","author":"G Ostuzzi","year":"2022","unstructured":"Ostuzzi G, Bertolini F, Tedeschi F, Vita G, Brambilla P, Del Fabro L, et al. Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants. World Psychiatry. 2022;21(2):295\u2013307. https:\/\/doi.org\/10.1002\/wps.20972.","journal-title":"World Psychiatry"},{"issue":"2","key":"1022_CR25","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/dom.13522","volume":"21","author":"D Siskind","year":"2019","unstructured":"Siskind D, Hahn M, Correll CU, Fink-Jensen A, Russell AW, Bak N, et al. Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: a systematic review and individual participant data meta-analysis. Diabetes Obes Metab. 2019;21(2):293\u2013302. https:\/\/doi.org\/10.1111\/dom.13522.","journal-title":"Diabetes Obes Metab"},{"key":"1022_CR26","doi-asserted-by":"publisher","DOI":"10.1017\/9781108553575","volume-title":"The clozapine handbook","author":"JM Meyer","year":"2019","unstructured":"Meyer JM, Stahl SM. The clozapine handbook. Cambridge: Cambridge University Press; 2019."},{"issue":"5","key":"1022_CR27","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1001\/jamapsychiatry.2021.0015","volume":"78","author":"K Hagi","year":"2021","unstructured":"Hagi K, Nosaka T, Dickinson D, Lindenmayer JP, Lee J, Friedman J, et al. Association between cardiovascular risk factors and cognitive impairment in people with schizophrenia: a systematic review and meta-analysis. JAMA Psychiat. 2021;78(5):510\u20138. https:\/\/doi.org\/10.1001\/jamapsychiatry.2021.0015.","journal-title":"JAMA Psychiat"},{"issue":"6","key":"1022_CR28","doi-asserted-by":"publisher","first-page":"e573","DOI":"10.4088\/JCP.13m08795","volume":"75","author":"P Manu","year":"2014","unstructured":"Manu P, Khan S, Radhakrishnan R, Russ MJ, Kane JM, Correll CU. Body mass index identified as an independent predictor of psychiatric readmission. J Clin Psychiatry. 2014;75(6):e573\u20137. https:\/\/doi.org\/10.4088\/JCP.13m08795.","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"1022_CR29","doi-asserted-by":"publisher","first-page":"17m12007","DOI":"10.4088\/JCP.17m12007","volume":"79","author":"O Godin","year":"2018","unstructured":"Godin O, Leboyer M, Sch\u00fcrhoff F, Llorca PM, Boyer L, Andre M, et al. Metabolic syndrome and illness severity predict relapse at 1-year follow-up in schizophrenia: the FACE-SZ cohort. J Clin Psychiatry. 2018;79(6):17m12007. https:\/\/doi.org\/10.4088\/JCP.17m12007.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"1022_CR30","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1093\/schbul\/sbu164","volume":"41","author":"M Torniainen","year":"2015","unstructured":"Torniainen M, Mittendorfer-Rutz E, Tanskanen A, Bj\u00f6rkenstam C, Suvisaari J, Alexanderson K, et al. Antipsychotic treatment and mortality in schizophrenia. Schizophr Bull. 2015;41(3):656\u201363. https:\/\/doi.org\/10.1093\/schbul\/sbu164.","journal-title":"Schizophr Bull"},{"issue":"1","key":"1022_CR31","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/wps.20699","volume":"19","author":"H Taipale","year":"2020","unstructured":"Taipale H, Tanskanen A, Meht\u00e4l\u00e4 J, Vattulainen P, Correll CU, Tiihonen J. 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). World Psychiatry. 2020;19(1):61\u20138. https:\/\/doi.org\/10.1002\/wps.20699.","journal-title":"World Psychiatry"},{"issue":"1","key":"1022_CR32","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/schbul\/sbab087","volume":"48","author":"M Solmi","year":"2022","unstructured":"Solmi M, Tiihonen J, L\u00e4hteenvuo M, Tanskanen A, Correll CU, Taipale H. Antipsychotics use is associated with greater adherence to cardiometabolic medications in patients with schizophrenia: results from a nationwide, within-subject design study. Schizophr Bull. 2022;48(1):166\u201375. https:\/\/doi.org\/10.1093\/schbul\/sbab087.","journal-title":"Schizophr Bull"},{"issue":"9690","key":"1022_CR33","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/s0140-6736(09)60742-x","volume":"374","author":"J Tiihonen","year":"2009","unstructured":"Tiihonen J, L\u00f6nnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009;374(9690):620\u20137. https:\/\/doi.org\/10.1016\/s0140-6736(09)60742-x.","journal-title":"Lancet"},{"issue":"3","key":"1022_CR34","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/sj.npp.1300027","volume":"28","author":"WK Kroeze","year":"2003","unstructured":"Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2003;28(3):519\u201326. https:\/\/doi.org\/10.1038\/sj.npp.1300027.","journal-title":"Neuropsychopharmacology"},{"key":"1022_CR35","doi-asserted-by":"publisher","first-page":"432","DOI":"10.3389\/fnins.2017.00432","volume":"11","author":"Z Freyberg","year":"2017","unstructured":"Freyberg Z, Aslanoglou D, Shah R, Ballon JS. Intrinsic and antipsychotic drug-induced metabolic dysfunction in schizophrenia. Front Neurosci. 2017;11:432. https:\/\/doi.org\/10.3389\/fnins.2017.00432.","journal-title":"Front Neurosci"},{"issue":"9","key":"1022_CR36","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.1073\/pnas.0611417104","volume":"104","author":"SF Kim","year":"2007","unstructured":"Kim SF, Huang AS, Snowman AM, Teuscher C, Snyder SH. From the cover: antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci USA. 2007;104(9):3456\u20139. https:\/\/doi.org\/10.1073\/pnas.0611417104.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"1022_CR37","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/mp.2011.109","volume":"17","author":"TA Lett","year":"2012","unstructured":"Lett TA, Wallace TJ, Chowdhury NI, Tiwari AK, Kennedy JL, M\u00fcller DJ. Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications. Mol Psychiatry. 2012;17(3):242\u201366. https:\/\/doi.org\/10.1038\/mp.2011.109.","journal-title":"Mol Psychiatry"},{"key":"1022_CR38","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jchemneu.2016.07.010","volume":"83\u201384","author":"AI Nash","year":"2017","unstructured":"Nash AI. Crosstalk between insulin and dopamine signaling: a basis for the metabolic effects of antipsychotic drugs. J Chem Neuroanat. 2017;83\u201384:59\u201368. https:\/\/doi.org\/10.1016\/j.jchemneu.2016.07.010.","journal-title":"J Chem Neuroanat"},{"issue":"1\u20133","key":"1022_CR39","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.schres.2011.06.004","volume":"131","author":"M Hahn","year":"2011","unstructured":"Hahn M, Chintoh A, Giacca A, Xu L, Lam L, Mann S, et al. Atypical antipsychotics and effects of muscarinic, serotonergic, dopaminergic and histaminergic receptor binding on insulin secretion in vivo: an animal model. Schizophr Res. 2011;131(1\u20133):90\u20135. https:\/\/doi.org\/10.1016\/j.schres.2011.06.004.","journal-title":"Schizophr Res"},{"issue":"11","key":"1022_CR40","doi-asserted-by":"publisher","first-page":"4741","DOI":"10.1038\/s41380-022-01798-y","volume":"27","author":"LN Castellani","year":"2022","unstructured":"Castellani LN, Pereira S, Kowalchuk C, Asgariroozbehani R, Singh R, Wu S, et al. Antipsychotics impair regulation of glucose metabolism by central glucose. Mol Psychiatry. 2022;27(11):4741\u201353. https:\/\/doi.org\/10.1038\/s41380-022-01798-y.","journal-title":"Mol Psychiatry"},{"issue":"9","key":"1022_CR41","doi-asserted-by":"publisher","first-page":"4467","DOI":"10.3390\/ijms22094467","volume":"22","author":"FV Gomes","year":"2021","unstructured":"Gomes FV, Grace AA. Beyond dopamine receptor antagonism: new targets for schizophrenia treatment and prevention. Int J Mol Sci. 2021;22(9):4467. https:\/\/doi.org\/10.3390\/ijms22094467.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"1022_CR42","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1177\/070674379704200205","volume":"42","author":"HE Lehmann","year":"1997","unstructured":"Lehmann HE, Ban TA. The history of the psychopharmacology of schizophrenia. Can J Psychiatry. 1997;42(2):152\u201362. https:\/\/doi.org\/10.1177\/070674379704200205.","journal-title":"Can J Psychiatry"},{"issue":"5562","key":"1022_CR43","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/261717a0","volume":"261","author":"P Seeman","year":"1976","unstructured":"Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic\/dopamine receptors. Nature. 1976;261(5562):717\u20139. https:\/\/doi.org\/10.1038\/261717a0.","journal-title":"Nature"},{"issue":"4238","key":"1022_CR44","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1126\/science.3854","volume":"192","author":"I Creese","year":"1976","unstructured":"Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 1976;192(4238):481\u20133. https:\/\/doi.org\/10.1126\/science.3854.","journal-title":"Science"},{"issue":"2","key":"1022_CR45","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1177\/0269881114563634","volume":"29","author":"O Howes","year":"2015","unstructured":"Howes O, McCutcheon R, Stone J. Glutamate and dopamine in schizophrenia: an update for the 21st century. J Psychopharmacol. 2015;29(2):97\u2013115. https:\/\/doi.org\/10.1177\/0269881114563634.","journal-title":"J Psychopharmacol"},{"issue":"1","key":"1022_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41537-019-0090-z","volume":"6","author":"SG Potkin","year":"2020","unstructured":"Potkin SG, Kane JM, Correll CU, Lindenmayer JP, Agid O, Marder SR, et al. The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research. NPJ Schizophr. 2020;6(1):1. https:\/\/doi.org\/10.1038\/s41537-019-0090-z.","journal-title":"NPJ Schizophr"},{"key":"1022_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18081689","author":"AC Yang","year":"2017","unstructured":"Yang AC, Tsai SJ. New targets for schizophrenia treatment beyond the dopamine hypothesis. Int J Mol Sci. 2017;18(8):1689. https:\/\/doi.org\/10.3390\/ijms18081689.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1022_CR48","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1017\/s1092852918001013","volume":"23","author":"SM Stahl","year":"2018","unstructured":"Stahl SM. Beyond the dopamine hypothesis of schizophrenia to three neural networks of psychosis: dopamine, serotonin, and glutamate. CNS Spectr. 2018;23(3):187\u201391. https:\/\/doi.org\/10.1017\/s1092852918001013.","journal-title":"CNS Spectr"},{"key":"1022_CR49","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3389\/fnins.2014.00395","volume":"8","author":"T Sumiyoshi","year":"2014","unstructured":"Sumiyoshi T, Kunugi H, Nakagome K. Serotonin and dopamine receptors in motivational and cognitive disturbances of schizophrenia. Front Neurosci. 2014;8:395. https:\/\/doi.org\/10.3389\/fnins.2014.00395.","journal-title":"Front Neurosci"},{"issue":"46","key":"1022_CR50","doi-asserted-by":"publisher","first-page":"11825","DOI":"10.1523\/jneurosci.3463-08.2008","volume":"28","author":"O Hikosaka","year":"2008","unstructured":"Hikosaka O, Sesack SR, Lecourtier L, Shepard PD. Habenula: crossroad between the basal ganglia and the limbic system. J Neurosci. 2008;28(46):11825\u20139. https:\/\/doi.org\/10.1523\/jneurosci.3463-08.2008.","journal-title":"J Neurosci"},{"issue":"1","key":"1022_CR51","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/(sici)1096-9861(19990428)407:1<130::aid-cne10>3.0.co;2-8","volume":"407","author":"KH Andres","year":"1999","unstructured":"Andres KH, von D\u00fcring M, Veh RW. Subnuclear organization of the rat habenular complexes. J Comp Neurol. 1999;407(1):130\u201350. https:\/\/doi.org\/10.1002\/(sici)1096-9861(19990428)407:1%3c130::aid-cne10%3e3.0.co;2-8.","journal-title":"J Comp Neurol"},{"issue":"1","key":"1022_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0149-7634(82)90003-3","volume":"6","author":"RJ Sutherland","year":"1982","unstructured":"Sutherland RJ. The dorsal diencephalic conduction system: a review of the anatomy and functions of the habenular complex. Neurosci Biobehav Rev. 1982;6(1):1\u201313. https:\/\/doi.org\/10.1016\/0149-7634(82)90003-3.","journal-title":"Neurosci Biobehav Rev"},{"issue":"4","key":"1022_CR53","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1177\/074873001129001980","volume":"16","author":"BD Goldman","year":"2001","unstructured":"Goldman BD. Mammalian photoperiodic system: formal properties and neuroendocrine mechanisms of photoperiodic time measurement. J Biol Rhythms. 2001;16(4):283\u2013301. https:\/\/doi.org\/10.1177\/074873001129001980.","journal-title":"J Biol Rhythms"},{"key":"1022_CR54","doi-asserted-by":"publisher","first-page":"636","DOI":"10.3389\/fnhum.2017.00636","volume":"11","author":"L Zhang","year":"2017","unstructured":"Zhang L, Wang H, Luan S, Yang S, Wang Z, Wang J, et al. Altered volume and functional connectivity of the habenula in schizophrenia. Front Hum Neurosci. 2017;11:636. https:\/\/doi.org\/10.3389\/fnhum.2017.00636.","journal-title":"Front Hum Neurosci"},{"issue":"45","key":"1022_CR55","doi-asserted-by":"publisher","first-page":"11482","DOI":"10.1523\/jneurosci.2350-16.2016","volume":"36","author":"PM Baker","year":"2016","unstructured":"Baker PM, Jhou T, Li B, Matsumoto M, Mizumori SJ, Stephenson-Jones M, et al. The lateral habenula circuitry: reward processing and cognitive control. J Neurosci. 2016;36(45):11482\u20138. https:\/\/doi.org\/10.1523\/jneurosci.2350-16.2016.","journal-title":"J Neurosci"},{"key":"1022_CR56","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.bbr.2014.09.016","volume":"277","author":"H Zhao","year":"2015","unstructured":"Zhao H, Zhang BL, Yang SJ, Rusak B. The role of lateral habenula-dorsal raphe nucleus circuits in higher brain functions and psychiatric illness. Behav Brain Res. 2015;277:89\u201398. https:\/\/doi.org\/10.1016\/j.bbr.2014.09.016.","journal-title":"Behav Brain Res"},{"key":"1022_CR57","doi-asserted-by":"publisher","first-page":"860","DOI":"10.3389\/fnhum.2013.00860","volume":"7","author":"FJ Meye","year":"2013","unstructured":"Meye FJ, Lecca S, Valentinova K, Mameli M. Synaptic and cellular profile of neurons in the lateral habenula. Front Hum Neurosci. 2013;7:860. https:\/\/doi.org\/10.3389\/fnhum.2013.00860.","journal-title":"Front Hum Neurosci"},{"key":"1022_CR58","doi-asserted-by":"publisher","first-page":"931","DOI":"10.3389\/fnhum.2013.00931","volume":"7","author":"H Viswanath","year":"2013","unstructured":"Viswanath H, Carter AQ, Baldwin PR, Molfese DL, Salas R. The medial habenula: still neglected. Front Hum Neurosci. 2013;7:931. https:\/\/doi.org\/10.3389\/fnhum.2013.00931.","journal-title":"Front Hum Neurosci"},{"issue":"2","key":"1022_CR59","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1093\/schbul\/sbaa128","volume":"47","author":"A Egerton","year":"2021","unstructured":"Egerton A, Murphy A, Donocik J, Anton A, Barker GJ, Collier T, et al. Dopamine and glutamate in antipsychotic-responsive compared with antipsychotic-nonresponsive psychosis: a multicenter positron emission tomography and magnetic resonance spectroscopy study (STRATA). Schizophr Bull. 2021;47(2):505\u201316. https:\/\/doi.org\/10.1093\/schbul\/sbaa128.","journal-title":"Schizophr Bull"},{"issue":"7","key":"1022_CR60","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1001\/jamapsychiatry.2016.0442","volume":"73","author":"K Merritt","year":"2016","unstructured":"Merritt K, Egerton A, Kempton MJ, Taylor MJ, McGuire PK. Nature of glutamate alterations in schizophrenia: a meta-analysis of proton magnetic resonance spectroscopy studies. JAMA Psychiat. 2016;73(7):665\u201374. https:\/\/doi.org\/10.1001\/jamapsychiatry.2016.0442.","journal-title":"JAMA Psychiat"},{"issue":"2","key":"1022_CR61","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s12264-014-1502-8","volume":"31","author":"Y Zhou","year":"2015","unstructured":"Zhou Y, Fan L, Qiu C, Jiang T. Prefrontal cortex and the dysconnectivity hypothesis of schizophrenia. Neurosci Bull. 2015;31(2):207\u201319. https:\/\/doi.org\/10.1007\/s12264-014-1502-8.","journal-title":"Neurosci Bull"},{"issue":"4","key":"1022_CR62","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1093\/scan\/nsx083","volume":"13","author":"M Comte","year":"2018","unstructured":"Comte M, Zendjidjian XY, Coull JT, Cancel A, Boutet C, Schneider FC, et al. Impaired cortico-limbic functional connectivity in schizophrenia patients during emotion processing. Soc Cogn Affect Neurosci. 2018;13(4):381\u201390. https:\/\/doi.org\/10.1093\/scan\/nsx083.","journal-title":"Soc Cogn Affect Neurosci."},{"issue":"5","key":"1022_CR63","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/s0006-3223(03)00168-9","volume":"54","author":"ML Phillips","year":"2003","unstructured":"Phillips ML, Drevets WC, Rauch SL, Lane R. Neurobiology of emotion perception I: the neural basis of normal emotion perception. Biol Psychiatry. 2003;54(5):504\u201314. https:\/\/doi.org\/10.1016\/s0006-3223(03)00168-9.","journal-title":"Biol Psychiatry"},{"issue":"9","key":"1022_CR64","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/mp.2008.65","volume":"13","author":"ML Phillips","year":"2008","unstructured":"Phillips ML, Ladouceur CD, Drevets WC. A neural model of voluntary and automatic emotion regulation: implications for understanding the pathophysiology and neurodevelopment of bipolar disorder. Mol Psychiatry. 2008;13(9):833\u201357. https:\/\/doi.org\/10.1038\/mp.2008.65.","journal-title":"Mol Psychiatry"},{"key":"1022_CR65","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.627198","volume":"12","author":"X Wang","year":"2021","unstructured":"Wang X, Yin Z, Sun Q, Jiang X, Chao L, Dai X, et al. Comparative study on the functional connectivity of amygdala and hippocampal neural circuits in patients with first-episode schizophrenia and other high-risk populations. Front Psychiatry. 2021;12: 627198. https:\/\/doi.org\/10.3389\/fpsyt.2021.627198.","journal-title":"Front Psychiatry."},{"issue":"7","key":"1022_CR66","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1176\/ajp.149.7.890","volume":"149","author":"DR Weinberger","year":"1992","unstructured":"Weinberger DR, Berman KF, Suddath R, Torrey EF. Evidence of dysfunction of a prefrontal-limbic network in schizophrenia: a magnetic resonance imaging and regional cerebral blood flow study of discordant monozygotic twins. Am J Psychiatry. 1992;149(7):890\u20137. https:\/\/doi.org\/10.1176\/ajp.149.7.890.","journal-title":"Am J Psychiatry"},{"issue":"2 Suppl","key":"1022_CR67","doi-asserted-by":"publisher","first-page":"106s","DOI":"10.1016\/s0893-133x(99)00046-9","volume":"21","author":"HY Meltzer","year":"1999","unstructured":"Meltzer HY. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology. 1999;21(2 Suppl):106s-s115. https:\/\/doi.org\/10.1016\/s0893-133x(99)00046-9.","journal-title":"Neuropsychopharmacology"},{"issue":"7","key":"1022_CR68","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.5257","volume":"11","author":"RS Patel","year":"2019","unstructured":"Patel RS, Bhela J, Tahir M, Pisati SR, Hossain S. Pimavanserin in Parkinson\u2019s disease-induced psychosis: a literature review. Cureus. 2019;11(7): e5257. https:\/\/doi.org\/10.7759\/cureus.5257.","journal-title":"Cureus."},{"issue":"3","key":"1022_CR69","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1124\/jpet.104.076968","volume":"312","author":"M Haj\u00f3s","year":"2005","unstructured":"Haj\u00f3s M, Hurst RS, Hoffmann WE, Krause M, Wall TM, Higdon NR, et al. The selective alpha7 nicotinic acetylcholine receptor agonist PNU-282987 [N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide hydrochloride] enhances GABAergic synaptic activity in brain slices and restores auditory gating deficits in anesthetized rats. J Pharmacol Exp Ther. 2005;312(3):1213\u201322. https:\/\/doi.org\/10.1124\/jpet.104.076968.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"1022_CR70","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1111\/j.1469-7793.2000.00515.x","volume":"527","author":"SN Sudweeks","year":"2000","unstructured":"Sudweeks SN, Yakel JL. Functional and molecular characterization of neuronal nicotinic ACh receptors in rat CA1 hippocampal neurons. J Physiol. 2000;527(3):515\u201328. https:\/\/doi.org\/10.1111\/j.1469-7793.2000.00515.x.","journal-title":"J Physiol"},{"issue":"1","key":"1022_CR71","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41537-020-0105-9","volume":"6","author":"M Caton","year":"2020","unstructured":"Caton M, Ochoa ELM, Barrantes FJ. The role of nicotinic cholinergic neurotransmission in delusional thinking. NPJ Schizophr. 2020;6(1):16. https:\/\/doi.org\/10.1038\/s41537-020-0105-9.","journal-title":"NPJ Schizophr"},{"issue":"Suppl 1","key":"1022_CR72","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4088\/JCP.10075su1.02","volume":"72","author":"CU Correll","year":"2011","unstructured":"Correll CU. What are we looking for in new antipsychotics? J Clin Psychiatry. 2011;72(Suppl 1):9\u201313. https:\/\/doi.org\/10.4088\/JCP.10075su1.02.","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"1022_CR73","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1176\/appi.ajp.2020.19121279","volume":"177","author":"CU Correll","year":"2020","unstructured":"Correll CU, Newcomer JW, Silverman B, DiPetrillo L, Graham C, Jiang Y, et al. Effects of olanzapine combined with samidorphan on weight gain in schizophrenia: a 24-week phase 3 study. Am J Psychiatry. 2020;177(12):1168\u201378. https:\/\/doi.org\/10.1176\/appi.ajp.2020.19121279.","journal-title":"Am J Psychiatry"},{"key":"1022_CR74","volume-title":"LYBALVI\u2122 (olanzapine and samidorphan) tablets, for oral use [prescribing information]","author":"I Alkermes","year":"2021","unstructured":"Alkermes I. LYBALVI\u2122 (olanzapine and samidorphan) tablets, for oral use [prescribing information]. Waltham: Alkermes, Inc.; 2021."},{"issue":"6","key":"1022_CR75","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1176\/appi.ajp.2018.18030280","volume":"176","author":"WF Martin","year":"2019","unstructured":"Martin WF, Correll CU, Weiden PJ, Jiang Y, Pathak S, DiPetrillo L, et al. Mitigation of olanzapine-induced weight gain with samidorphan, an opioid antagonist: a randomized double-blind phase 2 study in patients with schizophrenia. Am J Psychiatry. 2019;176(6):457\u201367. https:\/\/doi.org\/10.1176\/appi.ajp.2018.18030280.","journal-title":"Am J Psychiatry"},{"key":"1022_CR76","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.schres.2021.04.009","volume":"232","author":"RS Kahn","year":"2021","unstructured":"Kahn RS, Silverman BL, DiPetrillo L, Graham C, Jiang Y, Yin J, et al. A phase 3, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: results from the ENLIGHTEN-2 long-term extension. Schizophr Res. 2021;232:45\u201353. https:\/\/doi.org\/10.1016\/j.schres.2021.04.009.","journal-title":"Schizophr Res"},{"issue":"2","key":"1022_CR77","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1093\/schbul\/sbac144","volume":"49","author":"CU Correll","year":"2023","unstructured":"Correll CU, Stein E, Graham C, DiPetrillo L, Akerman S, Stanford AD, et al. Reduction in multiple cardiometabolic risk factors with combined olanzapine\/samidorphan compared with olanzapine: post hoc analyses from a 24-week phase 3 study. Schizophr Bull. 2023;49(2):454\u201363. https:\/\/doi.org\/10.1093\/schbul\/sbac144.","journal-title":"Schizophr Bull"},{"issue":"1","key":"1022_CR78","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/wps.20614","volume":"18","author":"D Vancampfort","year":"2019","unstructured":"Vancampfort D, Firth J, Correll CU, Solmi M, Siskind D, De Hert M, et al. The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta-review of meta-analyses of randomized controlled trials. World Psychiatry. 2019;18(1):53\u201366. https:\/\/doi.org\/10.1002\/wps.20614.","journal-title":"World Psychiatry"},{"issue":"17","key":"1022_CR79","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s40265-020-01393-x","volume":"80","author":"S Cernea","year":"2020","unstructured":"Cernea S, Dima L, Correll CU, Manu P. Pharmacological management of glucose dysregulation in patients treated with second-generation antipsychotics. Drugs. 2020;80(17):1763\u201381. https:\/\/doi.org\/10.1007\/s40265-020-01393-x.","journal-title":"Drugs"},{"issue":"1","key":"1022_CR80","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/wps.20714","volume":"19","author":"CU Correll","year":"2020","unstructured":"Correll CU, Sikich L, Reeves G, Johnson J, Keeton C, Spanos M, et al. Metformin add-on vs. antipsychotic switch vs. continued antipsychotic treatment plus healthy lifestyle education in overweight or obese youth with severe mental illness: results from the IMPACT trial. World Psychiatry. 2020;19(1):69\u201380. https:\/\/doi.org\/10.1002\/wps.20714.","journal-title":"World Psychiatry"},{"issue":"7","key":"1022_CR81","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1001\/jamapsychiatry.2017.1220","volume":"74","author":"JR Larsen","year":"2017","unstructured":"Larsen JR, Vedtofte L, Jakobsen MSL, Jespersen HR, Jakobsen MI, Svensson CK, et al. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial. JAMA Psychiat. 2017;74(7):719\u201328. https:\/\/doi.org\/10.1001\/jamapsychiatry.2017.1220.","journal-title":"JAMA Psychiat"},{"issue":"1","key":"1022_CR82","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/acps.12982","volume":"139","author":"CK Svensson","year":"2019","unstructured":"Svensson CK, Larsen JR, Vedtofte L, Jakobsen MSL, Jespersen HR, Jakobsen MI, et al. One-year follow-up on liraglutide treatment for prediabetes and overweight\/obesity in clozapine- or olanzapine-treated patients. Acta Psychiatr Scand. 2019;139(1):26\u201336. https:\/\/doi.org\/10.1111\/acps.12982.","journal-title":"Acta Psychiatr Scand"},{"key":"1022_CR83","doi-asserted-by":"publisher","first-page":"613","DOI":"10.3389\/fpsyt.2020.00613","volume":"11","author":"SF Sonnenschein","year":"2020","unstructured":"Sonnenschein SF, Gomes FV, Grace AA. Dysregulation of midbrain dopamine system and the pathophysiology of schizophrenia. Front Psychiatry. 2020;11:613. https:\/\/doi.org\/10.3389\/fpsyt.2020.00613.","journal-title":"Front Psychiatry."},{"issue":"10","key":"1022_CR84","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1176\/appi.ajp.2007.06081358","volume":"164","author":"RW Buchanan","year":"2007","unstructured":"Buchanan RW, Javitt DC, Marder SR, Schooler NR, Gold JM, McMahon RP, et al. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry. 2007;164(10):1593\u2013602. https:\/\/doi.org\/10.1176\/appi.ajp.2007.06081358.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"1022_CR85","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/s0006-3223(03)00707-8","volume":"55","author":"U Heresco-Levy","year":"2004","unstructured":"Heresco-Levy U, Ermilov M, Lichtenberg P, Bar G, Javitt DC. High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biol Psychiatry. 2004;55(2):165\u201371. https:\/\/doi.org\/10.1016\/s0006-3223(03)00707-8.","journal-title":"Biol Psychiatry"},{"issue":"7","key":"1022_CR86","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1001\/jamapsychiatry.2017.0624","volume":"74","author":"CU Correll","year":"2017","unstructured":"Correll CU, Rubio JM, Inczedy-Farkas G, Birnbaum ML, Kane JM, Leucht S. Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence. JAMA Psychiat. 2017;74(7):675\u201384. https:\/\/doi.org\/10.1001\/jamapsychiatry.2017.0624.","journal-title":"JAMA Psychiat"},{"key":"1022_CR87","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.742058","volume":"12","author":"JC Pei","year":"2021","unstructured":"Pei JC, Luo DZ, Gau SS, Chang CY, Lai WS. Directly and indirectly targeting the glycine modulatory site to modulate NMDA receptor function to address unmet medical needs of patients with schizophrenia. Front Psychiatry. 2021;12: 742058. https:\/\/doi.org\/10.3389\/fpsyt.2021.742058.","journal-title":"Front Psychiatry."},{"issue":"6","key":"1022_CR88","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1001\/jamapsychiatry.2014.163","volume":"71","author":"D Umbricht","year":"2014","unstructured":"Umbricht D, Alberati D, Martin-Facklam M, Borroni E, Youssef EA, Ostland M, et al. Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study. JAMA Psychiat. 2014;71(6):637\u201346. https:\/\/doi.org\/10.1001\/jamapsychiatry.2014.163.","journal-title":"JAMA Psychiat"},{"issue":"7","key":"1022_CR89","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.euroneuro.2014.03.007","volume":"24","author":"D Bugarski-Kirola","year":"2014","unstructured":"Bugarski-Kirola D, Wang A, Abi-Saab D, Bl\u00e4ttler T. A phase II\/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia\u2014results from the CandleLyte study. Eur Neuropsychopharmacol. 2014;24(7):1024\u201336. https:\/\/doi.org\/10.1016\/j.euroneuro.2014.03.007.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"S1","key":"1022_CR90","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1017\/s109285291900124x","volume":"24","author":"A Krogmann","year":"2019","unstructured":"Krogmann A, Peters L, von Hardenberg L, B\u00f6deker K, N\u00f6hles VB, Correll CU. Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities. CNS Spectr. 2019;24(S1):38\u201369. https:\/\/doi.org\/10.1017\/s109285291900124x.","journal-title":"CNS Spectr"},{"key":"1022_CR91","unstructured":"Neurocrine Biosciences I. Neurocrine biosciences announces top-line results from phase II INTERACT study evaluating luvadaxistat (NBI-1065844) for the treatment of negative symptoms and cognitive impairment associated with schizophrenia (CIAS). 2021. [cited April 29, 2022]. https:\/\/www.prnewswire.com\/news-releases\/neurocrine-biosciences-announces-top-line-results-from-phase-ii-interact-study-evaluating-luvadaxistat-nbi-1065844-for-the-treatment-of-negative-symptoms-and-cognitive-impairment-associated-with-schizophrenia-cias-301238086.html."},{"key":"1022_CR92","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3389\/fmolb.2017.00080","volume":"4","author":"G Molla","year":"2017","unstructured":"Molla G. Competitive inhibitors unveil structure\/function relationships in human d-amino acid oxidase. Front Mol Biosci. 2017;4:80. https:\/\/doi.org\/10.3389\/fmolb.2017.00080.","journal-title":"Front Mol Biosci"},{"key":"1022_CR93","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-023-01560-0","author":"P O'Donnell","year":"2023","unstructured":"O\u2019Donnell P, Dong C, Murthy V, Asgharnejad M, Du X, Summerfelt A, et al. The d-amino acid oxidase inhibitor luvadaxistat improves mismatch negativity in patients with schizophrenia in a randomized trial. Neuropsychopharmacology. 2023;48:1052\u201359. https:\/\/doi.org\/10.1038\/s41386-023-01560-0.","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"1022_CR94","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/wps.21056","volume":"22","author":"CU Correll","year":"2023","unstructured":"Correll CU, Solmi M, Cortese S, Fava M, H\u00f8jlund M, Kraemer HC, et al. The future of psychopharmacology: a critical appraisal of ongoing phase 2\/3 trials, and of some current trends aiming to de-risk trial programmes of novel agents. World Psychiatry. 2023;22(1):48\u201374. https:\/\/doi.org\/10.1002\/wps.21056.","journal-title":"World Psychiatry"},{"issue":"3","key":"1022_CR95","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/s2215-0366(20)30513-7","volume":"8","author":"WW Fleischhacker","year":"2021","unstructured":"Fleischhacker WW, Podhorna J, Gr\u00f6schl M, Hake S, Zhao Y, Huang S, et al. Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study. Lancet Psychiatry. 2021;8(3):191\u2013201. https:\/\/doi.org\/10.1016\/s2215-0366(20)30513-7.","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"1022_CR96","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/npp.2011.199","volume":"37","author":"CK Jones","year":"2012","unstructured":"Jones CK, Byun N, Bubser M. Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia. Neuropsychopharmacology. 2012;37(1):16\u201342. https:\/\/doi.org\/10.1038\/npp.2011.199.","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"1022_CR97","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1038\/s41386-018-0066-0","volume":"43","author":"GA Neves","year":"2018","unstructured":"Neves GA, Grace AA. \u03b17 nicotinic receptor-modulating agents reverse the hyperdopaminergic tone in the MAM model of schizophrenia. Neuropsychopharmacology. 2018;43(8):1712\u201320. https:\/\/doi.org\/10.1038\/s41386-018-0066-0.","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"1022_CR98","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/ntr\/nty034","volume":"21","author":"JR Tregellas","year":"2019","unstructured":"Tregellas JR, Wylie KP. Alpha7 nicotinic receptors as therapeutic targets in schizophrenia. Nicotine Tob Res. 2019;21(3):349\u201356. https:\/\/doi.org\/10.1093\/ntr\/nty034.","journal-title":"Nicotine Tob Res"},{"issue":"4","key":"1022_CR99","doi-asserted-by":"publisher","first-page":"191","DOI":"10.11919\/j.issn.1002-0829.217044","volume":"29","author":"Y Jin","year":"2017","unstructured":"Jin Y, Wang Q, Wang Y, Liu M, Sun A, Geng Z, et al. Alpha7 nAChR agonists for cognitive deficit and negative symptoms in schizophrenia: a meta-analysis of randomized double-blind controlled trials. Shanghai Arch Psychiatry. 2017;29(4):191\u20139. https:\/\/doi.org\/10.11919\/j.issn.1002-0829.217044.","journal-title":"Shanghai Arch Psychiatry"},{"issue":"13","key":"1022_CR100","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1038\/npp.2015.176","volume":"40","author":"RS Keefe","year":"2015","unstructured":"Keefe RS, Meltzer HA, Dgetluck N, Gawryl M, Koenig G, Moebius HJ, et al. Randomized, double-blind, placebo-controlled study of encenicline, an \u03b17 nicotinic acetylcholine receptor agonist, as a treatment for cognitive impairment in schizophrenia. Neuropsychopharmacology. 2015;40(13):3053\u201360. https:\/\/doi.org\/10.1038\/npp.2015.176.","journal-title":"Neuropsychopharmacology"},{"key":"1022_CR101","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.631589","volume":"12","author":"M Recio-Barbero","year":"2021","unstructured":"Recio-Barbero M, Segarra R, Zabala A, Gonz\u00e1lez-Fraile E, Gonz\u00e1lez-Pinto A, Ballesteros J. Cognitive enhancers in schizophrenia: a systematic review and meta-analysis of alpha-7 nicotinic acetylcholine receptor agonists for cognitive deficits and negative symptoms. Front Psychiatry. 2021;12: 631589. https:\/\/doi.org\/10.3389\/fpsyt.2021.631589.","journal-title":"Front Psychiatry."},{"issue":"14","key":"1022_CR102","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.2174\/1381612822666160127114010","volume":"22","author":"A Gibbons","year":"2016","unstructured":"Gibbons A, Dean B. The cholinergic system: an emerging drug target for schizophrenia. Curr Pharm Des. 2016;22(14):2124\u201333. https:\/\/doi.org\/10.2174\/1381612822666160127114010.","journal-title":"Curr Pharm Des"},{"issue":"8","key":"1022_CR103","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1176\/appi.ajp.2008.06091591","volume":"165","author":"A Shekhar","year":"2008","unstructured":"Shekhar A, Potter WZ, Lightfoot J, Lienemann J, Dub\u00e9 S, Mallinckrodt C, et al. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry. 2008;165(8):1033\u20139. https:\/\/doi.org\/10.1176\/appi.ajp.2008.06091591.","journal-title":"Am J Psychiatry"},{"key":"1022_CR104","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.21101083","author":"SM Paul","year":"2022","unstructured":"Paul SM, Yohn SE, Popiolek M, Miller AC, Felder CC. Muscarinic acetylcholine receptor agonists as novel treatments for schizophrenia. Am J Psychiatry. 2022;179:611\u201327. https:\/\/doi.org\/10.1176\/appi.ajp.21101083.","journal-title":"Am J Psychiatry"},{"issue":"9","key":"1022_CR105","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/nrd2379","volume":"6","author":"J Wess","year":"2007","unstructured":"Wess J, Eglen RM, Gautam D. Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. Nat Rev Drug Discov. 2007;6(9):721\u201333. https:\/\/doi.org\/10.1038\/nrd2379.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"1022_CR106","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/sj.mp.4001924","volume":"12","author":"TJ Raedler","year":"2007","unstructured":"Raedler TJ, Bymaster FP, Tandon R, Copolov D, Dean B. Towards a muscarinic hypothesis of schizophrenia. Mol Psychiatry. 2007;12(3):232\u201346. https:\/\/doi.org\/10.1038\/sj.mp.4001924.","journal-title":"Mol Psychiatry"},{"issue":"12","key":"1022_CR107","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1096\/fj.04-1575fje","volume":"18","author":"ET Tzavara","year":"2004","unstructured":"Tzavara ET, Bymaster FP, Davis RJ, Wade MR, Perry KW, Wess J, et al. M4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: relevance to the pathophysiology and treatment of related CNS pathologies. FASEB J. 2004;18(12):1410\u20132. https:\/\/doi.org\/10.1096\/fj.04-1575fje.","journal-title":"FASEB J"},{"issue":"3","key":"1022_CR108","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.baga.2016.02.001","volume":"6","author":"D Sulzer","year":"2016","unstructured":"Sulzer D, Cragg SJ, Rice ME. Striatal dopamine neurotransmission: regulation of release and uptake. Basal Ganglia. 2016;6(3):123\u201348. https:\/\/doi.org\/10.1016\/j.baga.2016.02.001.","journal-title":"Basal Ganglia."},{"issue":"5","key":"1022_CR109","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/j.1471-4159.2008.05711.x","volume":"107","author":"E Scarr","year":"2008","unstructured":"Scarr E, Dean B. Muscarinic receptors: do they have a role in the pathology and treatment of schizophrenia? J Neurochem. 2008;107(5):1188\u201395. https:\/\/doi.org\/10.1111\/j.1471-4159.2008.05711.x.","journal-title":"J Neurochem"},{"issue":"9","key":"1022_CR110","doi-asserted-by":"publisher","first-page":"4299","DOI":"10.3390\/ijms22094299","volume":"22","author":"S Acharya","year":"2021","unstructured":"Acharya S, Kim KM. Roles of the functional interaction between brain cholinergic and dopaminergic systems in the pathogenesis and treatment of schizophrenia and Parkinson\u2019s disease. Int J Mol Sci. 2021;22(9):4299. https:\/\/doi.org\/10.3390\/ijms22094299.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1022_CR111","doi-asserted-by":"publisher","first-page":"Rc190","DOI":"10.1523\/JNEUROSCI.22-01-j0001.2002","volume":"22","author":"GL Forster","year":"2002","unstructured":"Forster GL, Yeomans JS, Takeuchi J, Blaha CD. M5 muscarinic receptors are required for prolonged accumbal dopamine release after electrical stimulation of the pons in mice. J Neurosci. 2002;22(1):Rc190. https:\/\/doi.org\/10.1523\/JNEUROSCI.22-01-j0001.2002.","journal-title":"J Neurosci"},{"issue":"5","key":"1022_CR112","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1093\/schbul\/sbv030","volume":"41","author":"LA McCollum","year":"2015","unstructured":"McCollum LA, Walker CK, Roche JK, Roberts RC. Elevated excitatory input to the nucleus accumbens in schizophrenia: a postmortem ultrastructural study. Schizophr Bull. 2015;41(5):1123\u201332. https:\/\/doi.org\/10.1093\/schbul\/sbv030.","journal-title":"Schizophr Bull"},{"issue":"23","key":"1022_CR113","doi-asserted-by":"publisher","first-page":"4333","DOI":"10.1021\/jm990607u","volume":"43","author":"CC Felder","year":"2000","unstructured":"Felder CC, Bymaster FP, Ward J, DeLapp N. Therapeutic opportunities for muscarinic receptors in the central nervous system. J Med Chem. 2000;43(23):4333\u201353. https:\/\/doi.org\/10.1021\/jm990607u.","journal-title":"J Med Chem"},{"issue":"5","key":"1022_CR114","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/s0006-3223(00)00918-5","volume":"48","author":"JM Crook","year":"2000","unstructured":"Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B. Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation. Biol Psychiatry. 2000;48(5):381\u20138. https:\/\/doi.org\/10.1016\/s0006-3223(00)00918-5.","journal-title":"Biol Psychiatry"},{"issue":"6","key":"1022_CR115","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1176\/appi.ajp.158.6.918","volume":"158","author":"JM Crook","year":"2001","unstructured":"Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B. Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann\u2019s areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment. Am J Psychiatry. 2001;158(6):918\u201325. https:\/\/doi.org\/10.1176\/appi.ajp.158.6.918.","journal-title":"Am J Psychiatry"},{"key":"1022_CR116","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.606656","volume":"11","author":"ET van der Westhuizen","year":"2020","unstructured":"van der Westhuizen ET, Choy KHC, Valant C, McKenzie-Nickson S, Bradley SJ, Tobin AB, et al. Fine tuning muscarinic acetylcholine receptor signaling through allostery and bias. Front Pharmacol. 2020;11: 606656. https:\/\/doi.org\/10.3389\/fphar.2020.606656.","journal-title":"Front Pharmacol"},{"issue":"12","key":"1022_CR117","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.tips.2022.09.006","volume":"43","author":"SE Yohn","year":"2022","unstructured":"Yohn SE, Weiden PJ, Felder CC, Stahl SM. Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic. Trends Pharmacol Sci. 2022;43(12):1098\u2013112. https:\/\/doi.org\/10.1016\/j.tips.2022.09.006.","journal-title":"Trends Pharmacol Sci"},{"issue":"2","key":"1022_CR118","first-page":"782","volume":"299","author":"KJ Stanhope","year":"2001","unstructured":"Stanhope KJ, Mirza NR, Bickerdike MJ, Bright JL, Harrington NR, Hesselink MB, et al. The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat. J Pharmacol Exp Ther. 2001;299(2):782\u201392.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"1022_CR119","first-page":"901","volume":"290","author":"HE Shannon","year":"1999","unstructured":"Shannon HE, Hart JC, Bymaster FP, Calligaro DO, DeLapp NW, Mitch CH, et al. Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance response in rats. J Pharmacol Exp Ther. 1999;290(2):901\u20137.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"1022_CR120","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/s0920-9964(99)00138-3","volume":"42","author":"HE Shannon","year":"2000","unstructured":"Shannon HE, Rasmussen K, Bymaster FP, Hart JC, Peters SC, Swedberg MD, et al. Xanomeline, an M(1)\/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice. Schizophr Res. 2000;42(3):249\u201359. https:\/\/doi.org\/10.1016\/s0920-9964(99)00138-3.","journal-title":"Schizophr Res"},{"issue":"7","key":"1022_CR121","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1038\/sj.bjp.0702201","volume":"125","author":"J Watson","year":"1998","unstructured":"Watson J, Brough S, Coldwell MC, Gager T, Ho M, Hunter AJ, et al. Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors. Br J Pharmacol. 1998;125(7):1413\u201320. https:\/\/doi.org\/10.1038\/sj.bjp.0702201.","journal-title":"Br J Pharmacol"},{"issue":"9","key":"1022_CR122","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1177\/0269881116658989","volume":"30","author":"Y Odagaki","year":"2016","unstructured":"Odagaki Y, Kinoshita M, Ota T. Comparative analysis of pharmacological properties of xanomeline and N-desmethylclozapine in rat brain membranes. J Psychopharmacol. 2016;30(9):896\u2013912. https:\/\/doi.org\/10.1177\/0269881116658989.","journal-title":"J Psychopharmacol"},{"issue":"21","key":"1022_CR123","doi-asserted-by":"publisher","first-page":"9065","DOI":"10.1021\/jm501173q","volume":"57","author":"A Bonifazi","year":"2014","unstructured":"Bonifazi A, Yano H, Del Bello F, Farande A, Quaglia W, Petrelli R, et al. Synthesis and biological evaluation of a novel series of heterobivalent muscarinic ligands based on xanomeline and 1-[3-(4-butylpiperidin-1-yl)propyl]-1,2,3,4-tetrahydroquinolin-2-one (77-LH-28-1). J Med Chem. 2014;57(21):9065\u201377. https:\/\/doi.org\/10.1021\/jm501173q.","journal-title":"J Med Chem"},{"key":"1022_CR124","doi-asserted-by":"publisher","unstructured":"Bymaster FP, Whitesitt CA, Shannon HE, DeLapp N, Ward JS, Calligaro DO, et al. Xanomeline: a selective muscarinic agonist for the treatment of Alzheimer's disease. Drug Dev Res. 1997;40(2):158\u201370. https:\/\/doi.org\/10.1002\/(SICI)1098-2299(199702)40:2<158::AID-DDR6>3.0.CO;2-K.","DOI":"10.1002\/(SICI)1098-2299(199702)40:2<158::AID-DDR6>3.0.CO;2-K"},{"issue":"4","key":"1022_CR125","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s00213-011-2247-y","volume":"216","author":"A Newman-Tancredi","year":"2011","unstructured":"Newman-Tancredi A, Kleven MS. Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties. Psychopharmacology. 2011;216(4):451\u201373. https:\/\/doi.org\/10.1007\/s00213-011-2247-y.","journal-title":"Psychopharmacology"},{"issue":"4","key":"1022_CR126","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1093\/schbul\/sbi058","volume":"31","author":"JJ Hagan","year":"2005","unstructured":"Hagan JJ, Jones DN. Predicting drug efficacy for cognitive deficits in schizophrenia. Schizophr Bull. 2005;31(4):830\u201353. https:\/\/doi.org\/10.1093\/schbul\/sbi058.","journal-title":"Schizophr Bull"},{"issue":"4","key":"1022_CR127","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1001\/archneur.1997.00550160091022","volume":"54","author":"NC Bodick","year":"1997","unstructured":"Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol. 1997;54(4):465\u201373. https:\/\/doi.org\/10.1001\/archneur.1997.00550160091022.","journal-title":"Arch Neurol"},{"issue":"8","key":"1022_CR128","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1056\/NEJMoa2017015","volume":"384","author":"SK Brannan","year":"2021","unstructured":"Brannan SK, Sawchak S, Miller AC, Lieberman JA, Paul SM, Breier A. Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia. N Engl J Med. 2021;384(8):717\u201326. https:\/\/doi.org\/10.1056\/NEJMoa2017015.","journal-title":"N Engl J Med"},{"key":"1022_CR129","unstructured":"Karuna Therapeutics, Inc. Karuna Therapeutics announces positive results from phase 3 EMERGENT-2 trial of KarXT in schizophrenia. 2022. [cited August 25, 2022]. https:\/\/investors.karunatx.com\/news-releases\/news-release-details\/karuna-therapeutics-announces-positive-results-phase-3-emergent."},{"issue":"10369","key":"1022_CR130","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1016\/s0140-6736(22)01990-0","volume":"400","author":"JH Krystal","year":"2022","unstructured":"Krystal JH, Kane JM, Correll CU, Walling DP, Leoni M, Duvvuri S, et al. Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial. Lancet. 2022;400(10369):2210\u201320. https:\/\/doi.org\/10.1016\/s0140-6736(22)01990-0.","journal-title":"Lancet"},{"issue":"5","key":"1022_CR131","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/mp.2012.57","volume":"18","author":"FG Revel","year":"2013","unstructured":"Revel FG, Moreau JL, Pouzet B, Mory R, Bradaia A, Buchy D, et al. A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight. Mol Psychiatry. 2013;18(5):543\u201356. https:\/\/doi.org\/10.1038\/mp.2012.57.","journal-title":"Mol Psychiatry"},{"issue":"16","key":"1022_CR132","doi-asserted-by":"publisher","first-page":"8966","DOI":"10.1073\/pnas.151105198","volume":"98","author":"B Borowsky","year":"2001","unstructured":"Borowsky B, Adham N, Jones KA, Raddatz R, Artymyshyn R, Ogozalek KL, et al. Trace amines: identification of a family of mammalian G protein-coupled receptors. Proc Natl Acad Sci USA. 2001;98(16):8966\u201371. https:\/\/doi.org\/10.1073\/pnas.151105198.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"1022_CR133","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1124\/mol.60.6.1181","volume":"60","author":"JR Bunzow","year":"2001","unstructured":"Bunzow JR, Sonders MS, Arttamangkul S, Harrison LM, Zhang G, Quigley DI, et al. Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol Pharmacol. 2001;60(6):1181\u20138. https:\/\/doi.org\/10.1124\/mol.60.6.1181.","journal-title":"Mol Pharmacol"},{"issue":"24","key":"1022_CR134","doi-asserted-by":"publisher","first-page":"13185","DOI":"10.3390\/ijms222413185","volume":"22","author":"N Dedic","year":"2021","unstructured":"Dedic N, Dworak H, Zeni C, Rutigliano G, Howes OD. Therapeutic potential of TAAR1 agonists in schizophrenia: evidence from preclinical models and clinical studies. Int J Mol Sci. 2021;22(24):13185. https:\/\/doi.org\/10.3390\/ijms222413185.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1022_CR135","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1124\/pr.117.015305","volume":"70","author":"RR Gainetdinov","year":"2018","unstructured":"Gainetdinov RR, Hoener MC, Berry MD. Trace amines and their receptors. Pharmacol Rev. 2018;70(3):549\u2013620. https:\/\/doi.org\/10.1124\/pr.117.015305.","journal-title":"Pharmacol Rev"},{"issue":"2","key":"1022_CR136","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s10571-019-00743-y","volume":"40","author":"G Rutigliano","year":"2020","unstructured":"Rutigliano G, Zucchi R. Molecular variants in human trace amine-associated receptors and their implications in mental and metabolic disorders. Cell Mol Neurobiol. 2020;40(2):239\u201355. https:\/\/doi.org\/10.1007\/s10571-019-00743-y.","journal-title":"Cell Mol Neurobiol"},{"key":"1022_CR137","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-022-01421-2","author":"M Saarinen","year":"2022","unstructured":"Saarinen M, Mantas I, Flais I, \u00c5gren R, Sahlholm K, Millan MJ, et al. TAAR1 dependent and independent actions of the potential antipsychotic and dual TAAR1\/5-HT(1A) receptor agonist SEP-383856. Neuropsychopharmacology. 2022. https:\/\/doi.org\/10.1038\/s41386-022-01421-2.","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"1022_CR138","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1124\/mol.111.073304","volume":"80","author":"S Espinoza","year":"2011","unstructured":"Espinoza S, Salahpour A, Masri B, Sotnikova TD, Messa M, Barak LS, et al. Functional interaction between trace amine-associated receptor 1 and dopamine D2 receptor. Mol Pharmacol. 2011;80(3):416\u201325. https:\/\/doi.org\/10.1124\/mol.111.073304.","journal-title":"Mol Pharmacol"},{"issue":"3","key":"1022_CR139","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1124\/jpet.107.132647","volume":"324","author":"L Lindemann","year":"2008","unstructured":"Lindemann L, Meyer CA, Jeanneau K, Bradaia A, Ozmen L, Bluethmann H, et al. Trace amine-associated receptor 1 modulates dopaminergic activity. J Pharmacol Exp Ther. 2008;324(3):948\u201356. https:\/\/doi.org\/10.1124\/jpet.107.132647.","journal-title":"J Pharmacol Exp Ther"},{"issue":"16","key":"1022_CR140","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1056\/NEJMoa1911772","volume":"382","author":"KS Koblan","year":"2020","unstructured":"Koblan KS, Kent J, Hopkins SC, Krystal JH, Cheng H, Goldman R, et al. A non-D2-receptor-binding drug for the treatment of schizophrenia. N Engl J Med. 2020;382(16):1497\u2013506. https:\/\/doi.org\/10.1056\/NEJMoa1911772.","journal-title":"N Engl J Med"},{"issue":"7","key":"1022_CR141","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/j.1601-183X.2006.00292.x","volume":"6","author":"TD Wolinsky","year":"2007","unstructured":"Wolinsky TD, Swanson CJ, Smith KE, Zhong H, Borowsky B, Seeman P, et al. The trace amine 1 receptor knockout mouse: an animal model with relevance to schizophrenia. Genes Brain Behav. 2007;6(7):628\u201339. https:\/\/doi.org\/10.1111\/j.1601-183X.2006.00292.x.","journal-title":"Genes Brain Behav"},{"issue":"20","key":"1022_CR142","doi-asserted-by":"publisher","first-page":"8485","DOI":"10.1073\/pnas.1103029108","volume":"108","author":"FG Revel","year":"2011","unstructured":"Revel FG, Moreau JL, Gainetdinov RR, Bradaia A, Sotnikova TD, Mory R, et al. TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity. Proc Natl Acad Sci USA. 2011;108(20):8485\u201390. https:\/\/doi.org\/10.1073\/pnas.1103029108.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1022_CR143","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.pharmthera.2017.07.002","volume":"180","author":"MD Berry","year":"2017","unstructured":"Berry MD, Gainetdinov RR, Hoener MC, Shahid M. Pharmacology of human trace amine-associated receptors: therapeutic opportunities and challenges. Pharmacol Ther. 2017;180:161\u201380. https:\/\/doi.org\/10.1016\/j.pharmthera.2017.07.002.","journal-title":"Pharmacol Ther"},{"key":"1022_CR144","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.brainres.2014.04.029","volume":"1568","author":"JL McGuire","year":"2014","unstructured":"McGuire JL, Hammond JH, Yates SD, Chen D, Haroutunian V, Meador-Woodruff JH, et al. Altered serine\/threonine kinase activity in schizophrenia. Brain Res. 2014;1568:42\u201354. https:\/\/doi.org\/10.1016\/j.brainres.2014.04.029.","journal-title":"Brain Res"},{"issue":"11","key":"1022_CR145","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1016\/j.euroneuro.2015.08.011","volume":"25","author":"A Harmeier","year":"2015","unstructured":"Harmeier A, Obermueller S, Meyer CA, Revel FG, Buchy D, Chaboz S, et al. Trace amine-associated receptor 1 activation silences GSK3\u03b2 signaling of TAAR1 and D2R heteromers. Eur Neuropsychopharmacol. 2015;25(11):2049\u201361. https:\/\/doi.org\/10.1016\/j.euroneuro.2015.08.011.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1","key":"1022_CR146","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1021\/acsmedchemlett.1c00527","volume":"13","author":"MLR Heffernan","year":"2022","unstructured":"Heffernan MLR, Herman LW, Brown S, Jones PG, Shao L, Hewitt MC, et al. Ulotaront: a TAAR1 agonist for the treatment of schizophrenia. ACS Med Chem Lett. 2022;13(1):92\u20138. https:\/\/doi.org\/10.1021\/acsmedchemlett.1c00527.","journal-title":"ACS Med Chem Lett"},{"key":"1022_CR147","doi-asserted-by":"publisher","first-page":"987","DOI":"10.3389\/fphar.2017.00987","volume":"8","author":"G Rutigliano","year":"2017","unstructured":"Rutigliano G, Accorroni A, Zucchi R. The case for TAAR1 as a modulator of central nervous system function. Front Pharmacol. 2017;8:987. https:\/\/doi.org\/10.3389\/fphar.2017.00987.","journal-title":"Front Pharmacol"},{"key":"1022_CR148","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222111576","author":"DA Barnes","year":"2021","unstructured":"Barnes DA, Galloway DA, Hoener MC, Berry MD, Moore CS. TAAR1 expression in human macrophages and brain tissue: a potential novel facet of MS neuroinflammation. Int J Mol Sci. 2021;22(21):11576. https:\/\/doi.org\/10.3390\/ijms222111576.","journal-title":"Int J Mol Sci"},{"key":"1022_CR149","doi-asserted-by":"publisher","first-page":"680","DOI":"10.3389\/fphar.2018.00680","volume":"9","author":"SL Christian","year":"2018","unstructured":"Christian SL, Berry MD. Trace amine-associated receptors as novel therapeutic targets for immunomodulatory disorders. Front Pharmacol. 2018;9:680. https:\/\/doi.org\/10.3389\/fphar.2018.00680.","journal-title":"Front Pharmacol"},{"issue":"12","key":"1022_CR150","doi-asserted-by":"publisher","first-page":"4401","DOI":"10.1074\/jbc.RA118.005464","volume":"294","author":"ES Michael","year":"2019","unstructured":"Michael ES, Covic L, Kuliopulos A. Trace amine-associated receptor 1 (TAAR1) promotes anti-diabetic signaling in insulin-secreting cells. J Biol Chem. 2019;294(12):4401\u201311. https:\/\/doi.org\/10.1074\/jbc.RA118.005464.","journal-title":"J Biol Chem"},{"key":"1022_CR151","unstructured":"Ghost. Scoop: Roche scraps one of two schizophrenia PhII trials due to missed primary endpoint. 2022. [cited August 29, 2022]. https:\/\/www.hotstock-insights.com\/scoop-roche-scraps-one-of-two-schizophrenia-phii-trials-due-to-missed-primary-endpoint\/."},{"issue":"1","key":"1022_CR152","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41537-021-00190-z","volume":"7","author":"CU Correll","year":"2021","unstructured":"Correll CU, Koblan KS, Hopkins SC, Li Y, Heather D, Goldman R, et al. Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study. NPJ Schizophr. 2021;7(1):63. https:\/\/doi.org\/10.1038\/s41537-021-00190-z.","journal-title":"NPJ Schizophr"},{"issue":"1","key":"1022_CR153","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/jpet.119.260281","volume":"371","author":"N Dedic","year":"2019","unstructured":"Dedic N, Jones PG, Hopkins SC, Lew R, Shao L, Campbell JE, et al. SEP-363856, a novel psychotropic agent with a unique, non-D(2) receptor mechanism of action. J Pharmacol Exp Ther. 2019;371(1):1\u201314. https:\/\/doi.org\/10.1124\/jpet.119.260281.","journal-title":"J Pharmacol Exp Ther"},{"key":"1022_CR154","doi-asserted-by":"crossref","unstructured":"Dedic N, Jones PG, Hajos-Korcsok E, Synan C, Wu S, Anacker C, et al. TAAR1 agonist ulotaront improves glycemic control and reduces body weight in rodent models of diabetes, obesity and iatrogenic weight gain [poster]. Presented at Schizophrenia International Research Society Congress, April 6\u201310, 2022, Florence, Italy; 2022.","DOI":"10.1017\/S1092852923002079"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-023-01022-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-023-01022-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-023-01022-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T14:29:38Z","timestamp":1690468178000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-023-01022-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":154,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["1022"],"URL":"https:\/\/doi.org\/10.1007\/s40263-023-01022-7","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"21 June 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Medical writing and editorial assistance, including preparing the outline and draft, incorporating revisions, literature searching, and journal styling, were provided by Debika Chatterjea, PhD, and Stephen Bublitz, ELS, of PharmaWrite, LLC (Princeton, NJ, USA), and were funded by Sumitomo Pharma America, Inc. and Otsuka Pharmaceuticals Development & Commercialization, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Dr. Meyer has been a consultant and\/or advisor to or has received honoraria from Acadia, Alkermes, AbbVie, Cerevel, Intra-Cellular, Karuna, Neurocrine, Noven, Otsuka, Relmada, Sunovion, and Teva. Dr. Correll has been a consultant and\/or advisor to or has received honoraria from AbbVie, Acadia, Alkermes, Allergan, Angelini, Aristo, Boehringer-Ingelheim, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Gedeon Richter, Hikma, Holmusk, Intra-Cellular Therapies, Janssen\/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Merck, Mindpax, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Newron, Noven, Otsuka, Pharmabrain, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Seqirus, SK Life Science, Sunovion, Sun Pharma, Supernus, Takeda, Teva, and Viatris. He provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Lundbeck, Relmada, Reviva, Rovi, Supernus, and Teva. He has received grant support from Janssen and Takeda. He is a stock option holder of Cardio Diagnostics, Mindpax, LB Pharma, and Quantic. He received support for travel, manuscript preparation or other reason from Angelini, Gedeon Richter, Janssen\/J&J, Karuna, Lundbeck, Mylan, Otsuka, Recordati, Sunovion, Teva, and Viatris. He has received payment for lectures including service on speakers bureaus from AbbVie, Angelini, Aristo, Damitsa, Gedeon Richter, Hikma, Intra-Cellular Therapies, Janssen\/J&J, Lundbeck, Mitsubishi Tanabe Pharma, Mylan, Otsuka, Recordati, Seqirus, Sunovion, Takeda, and Viatris.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}